Latest Earnings Results: Q2 '26
Estimated EPS
$0.11
Reported EPS
$0.16
Surprise
+43.99%
Estimated Rev
$20.2M
Reported Rev
$20.5M
Surprise
+1.46%
• Reported GAAP EPS of -$0.04 down -150.00% YoY • Reported revenue of $20.5M down -29.77% YoY • OptimizeRx Corp is reiterating its fiscal year 2026 guidance, expecting revenue of $95 million to $100 million and adjusted EBITDA of $21 million to $25 million for the full year.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $0.18 | -- | -- | N/A |
Q2 '26 | $0.11 | $0.16 | 43.99% | BEAT |
Q1 '26 | $0.00 | $0.14 | 4100.42% | BEAT |
Q4 '25 | $0.22 | $0.51 | 127.32% | BEAT |
Q3 '25 | $0.04 | $0.20 | 442.01% | BEAT |